The goal of our proposed research is to develop a Brucella vaccine that is safe for human use. Our approach has explored the use of live attenuated vaccines, since subunit vaccines have shown little real promise. Our approach combines the optimal features of a deliverable vaccine that is safe, free of side effects and efficacious in humans with enhanced immune stimulation through microencapsulation. The competitive advantages and innovations of our approach are: (1) use of a highly attenuated, safe, gene knockout, live B. melitensis mutants;(2) manufacturing with unique disposable closed system technologies, and (3) oral/intranasal delivery in a novel microencapsulation-mediated controlled release formula to optimally provide the long term mucosal immunostimulation required for protective immunity. Based upon our preliminary data, we postulate that our vaccine delivery system will ultimately be storage stable, administered orally or intranasally, and generally applicable to a number of select agents. We present a welldesigned 5-year timeline with milestones for developing GMP-produced vaccine for vaccination-aerosol challenge studies in non-human primates as a pathway to a clinical Investigational New Drug studies on the path to FDA Biological License Application. The development of the proposed product takes full advantage of a strong team and ongoing research with bacterial genetics and testing in multiple animal models coupled with novel manufacturing and microencapsulation technologies that balance product safety, stability, costs, and potency.
No human brucellosis vaccine is available despite the continued presence of the organism in 86 countries in which tens of thousands of humans are treated for brucellosis annually. Although the ongoing threat to the US has been greatly reduced, the potential threat to the United States remains high and retains both public health and economic impact.
|Navarro, Juan-Carlos; Giambalvo, Dileyvic; Hernandez, Rosa et al. (2016) Isolation of Madre de Dios Virus (Orthobunyavirus; Bunyaviridae), an Oropouche Virus Species Reassortant, from a Monkey in Venezuela. Am J Trop Med Hyg 95:328-38|
|Park, Arnold; Yun, Tatyana; Hill, Terence E et al. (2016) Optimized P2A for reporter gene insertion into Nipah virus results in efficient ribosomal skipping and wild-type lethality. J Gen Virol 97:839-43|
|Aghazadeh, Amirali; Lin, Adam Y; Sheikh, Mona A et al. (2016) Universal microbial diagnostics using random DNA probes. Sci Adv 2:e1600025|
|Inglis, Fiona M; Lee, Kim M; Chiu, Kevin B et al. (2016) Neuropathogenesis of Chikungunya infection: astrogliosis and innate immune activation. J Neurovirol 22:140-8|
|Hatcher, Christopher L; Mott, Tiffany M; Muruato, Laura A et al. (2016) Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders. Infect Immun 84:2345-54|
|Chen, Hui; HagstrÃ¶m, Anna E V; Kim, Jinsu et al. (2016) Flotation Immunoassay: Masking the Signal from Free Reporters in Sandwich Immunoassays. Sci Rep 6:24297|
|Crannell, Zachary Austin; Cabada, Miguel Mauricio; Castellanos-Gonzalez, Alejandro et al. (2015) Recombinase polymerase amplification-based assay to diagnose Giardia in stool samples. Am J Trop Med Hyg 92:583-7|
|Walker, David H; Dumler, J Stephen (2015) The role of CD8 T lymphocytes in rickettsial infections. Semin Immunopathol 37:289-99|
|Mott, Tiffany M; Vijayakumar, Sudhamathi; Sbrana, Elena et al. (2015) Characterization of the Burkholderia mallei tonB Mutant and Its Potential as a Backbone Strain for Vaccine Development. PLoS Negl Trop Dis 9:e0003863|
|Gregory, Anthony E; Judy, Barbara M; Qazi, Omar et al. (2015) A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine 11:447-56|
Showing the most recent 10 out of 362 publications